SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Pedersen M. W.) srt2:(2000-2004)"

Sökning: WFRF:(Pedersen M. W.) > (2000-2004)

  • Resultat 1-10 av 10
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  • Bock G., Roberts R.G., Kissling E., Achauer A., Alingahi J., Bruneton M., Friedrich W., Grad M. Guterch A., Hjelt S-E., Hyvönen T., Ikonen J-P., Komminaho K., Korja A, Heikkinen P., Kozolovaskaya E., Nevsky M.V., Pavlenkova N., Pedersen H., Plomerova J. (författare)
  • Seismic probing of Archean and Proterozoic Lithosphere in Fennoscandia.
  • 2001
  • Ingår i: EOS Transactions American Geophysical Union. - : American Geophysical Union. ; 82, s. 621,628-629
  • Tidskriftsartikel (refereegranskat)
  •  
4.
  • Bruneton, M., V. Farra, H. A. Pedersen & the SVEKALAPKO Seismic Tomography Working Group, (G. Bock, U. Achauer, A. Alinaghi, J. Ansorge, M. Bruneton, W. Friederich, M. Grad, A. Guterch, S.-E. Hjelt, T. Hyvönen, J.-P. Ikonen, E. Kissling, K. Komminaho, A. (författare)
  • Non-linear surface wave phase velocity inversion based on ray theory.
  • 2002
  • Ingår i: Geophys. J. Int. ; 151, s. 583-596
  • Tidskriftsartikel (refereegranskat)
  •  
5.
  • Cleland, J. G., et al. (författare)
  • A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET)
  • 2004
  • Ingår i: Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. - 0920-3206. ; 18:2, s. 139-52
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND & AIMS: The COMET trial was a prospective, double-blind, randomised trial comparing carvedilol, a comprehensive adrenergic receptor antagonist, with metoprolol, a beta-1-selective agent in patients with heart failure and left ventricular systolic dysfunction. The trial showed a reduction in mortality with carvedilol that was consistent across subgroups. The purpose of this report is to describe in greater detail the heterogeneity of this population at baseline with particular reference to the impact of symptomatic severity, age and gender on patient characteristics. METHODS: A descriptive report using data entered in the COMET study data-base. RESULTS: The characteristics of the population studied were similar to those reported in previous trials of beta-blockers. Almost all patients were receiving diuretics and ACE inhibitors with few patients taking angiotensin receptor blockers. As expected, older patients had more co-morbidity. Older patients and women reported worse symptoms and poorer well-being despite similar ventricular dimensions and systolic dysfunction. NT-proBNP was higher in patients with more severe symptoms and older patients but not in women, although differences in NT-proBNP may have been confounded by differences in renal function. CONCLUSION: Age and gender, as well as the severity of cardiac dysfunction, appear to have an important effect on the severity of heart failure symptoms and patient 'well-being'. This could have important implications for the relationship between symptoms and prognosis and therefore the way in which patients are selected for clinical trials and the goals of treatment. This will be the subject of further analyses.
  •  
6.
  • Torkar, K., Riedler, W., Escoubet, C.P., Fehringer, M., Schmidt, R., Grard, R.J., Arends, H., Rudenauer, F., Steiger, W., Narheim, B.T., Svenes, K., Torbert, R., Andre, M., Fazakerley, A., Goldstein, R., Olsen, R.C., Pedersen, A., Whipple, E. and Zhao, H. (författare)
  • Active spacecraft potential control for Cluster - implementation and first results
  • 2001
  • Ingår i: Annales Geophysicae. ; 9:10-12, s. 1289-1302
  • Tidskriftsartikel (refereegranskat)abstract
    • Electrostatic charging of a spacecraft modifies the distribution of electrons and ions before the particles enter the sensors mounted on the spacecraft body. The floating potential of magnetospheric satellites in sunlight very often reaches several tens o
  •  
7.
  • Reims, H. M., et al. (författare)
  • Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study
  • 2004
  • Ingår i: J Hum Hypertens. - : Springer Science and Business Media LLC. - 0950-9240 .- 1476-5527. ; 18:6, s. 381-9
  • Tidskriftsartikel (refereegranskat)abstract
    • The Losartan Intervention For End point reduction in hypertension (LIFE) study showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke, and myocardial infarction in hypertensives with left ventricular hypertrophy. We compared hazard ratios (HR) in 4287 and 685 participants who reported intakes of 1-7 and >8 drinks/week at baseline, respectively, with those in 4216 abstainers, adjusting for gender, age, smoking, exercise, and race. Within categories, clinical baseline characteristics, numbers randomized to losartan and atenolol, and blood pressure (BP) lowering were similar on the drug regimens. Overall BP control (<140/90 mmHg) at end of follow-up was similar in the categories. Composite end point rate was lower with 1-7 (24/1000 years; HR 0.87, P<0.05) and >8 drinks/week (26/1000 years; HR 0.80, NS) than in abstainers (27/1000 years). Myocardial infarction risk was reduced in both drinking categories (HR 0.76, P<0.05 and HR 0.29, P<0.001, respectively), while stroke risk tended to increase with >8 drinks/week (HR 1.21, NS). Composite risk was significantly reduced with losartan compared to atenolol only in abstainers (HR 0.81 95% confidence interval, CI (0.68, 0.96), P<0.05), while benefits for stroke risk reduction were similar among participants consuming 1-7 drinks/week (HR 0.73, P<0.05) and abstainers (HR 0.72, P<0.01). Despite different treatment benefits, alcohol-treatment interactions were nonsignificant. In conclusion, moderate alcohol consumption does not change the marked stroke risk reduction with losartan compared to atenolol in high-risk hypertensives. Alcohol reduces the risk of myocardial infarction, while the risk of stroke tends to increase with high intake.
  •  
8.
  • Reims, H. M., et al. (författare)
  • Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study
  • 2004
  • Ingår i: Blood Press. - : Informa UK Limited. - 0803-7051 .- 1651-1999. ; 13:6, s. 376-84
  • Tidskriftsartikel (refereegranskat)abstract
    • We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy. We compared hazard ratios in 4656 never-smokers, and 3033 previous and 1499 current smokers, adjusting for gender, age, alcohol intake, exercise and race. Composite endpoint rate was higher in previous (28/1000 years), as well as current (39/1000 years) smokers than in never-smokers (21/1000 years). Composite (hazard ratio 0.78, 95% CI 0.65-0.94, p < 0.01) and stroke (hazard ratio 0.61, 95% CI 0.47-0.80], p < 0.001) risks were lower with losartan than atenolol in never-smokers, but not significantly in previous smokers. Drug regimens did not differ in current smokers (composite hazard ratio 0.99, stroke hazard ratio 0.94). Smoking-treatment interactions were non-significant, but a borderline significant trend (p = 0.05) suggested decreasing benefit of losartan vs atenolol for stroke prevention from never- to previous to current smoking status. Smoking increased cardiovascular risk markedly in the LIFE study. The benefit of losartan vs atenolol is consistent with the overall conclusion of the LIFE study, although the treatment effect appeared largest in non-smokers.
  •  
9.
  • Li, W X, et al. (författare)
  • Oxidation of Pt(110)
  • 2004
  • Ingår i: Physical Review Letters. - 0031-9007 .- 1079-7114. ; 93:14, s. 146104-
  • Tidskriftsartikel (refereegranskat)abstract
    • Using scanning tunneling microscopy and temperature programed desorption we investigate the Pt(110) surface under strongly oxidizing conditions involving either high-pressure O-2 or atomic oxygen exposure. At low temperatures, only disordered Pt oxide structures are observed. After annealing ordered surface oxide islands are observed to coexist with a highly stable reconstructed (12x2)-O chemisorption structure. From density functional theory calculations a model for the surface oxide phase is revealed. The phase is found to be metastable, and its presence is explained in terms of stabilizing defects in the chemisorption layer and reduced Pt mobility.
  •  
10.
  • Moen, J., Holtet, J.A., Pedersen, A., Lybekk, B., Svenes, K., Oksavik, K., Denig, W.F., Lucek, E., Søraas, F. and André, M. (författare)
  • Cluster boundary-layer measurements and optical observations at magnetically conjugate sites.
  • 2001
  • Ingår i: Annales Geophysicae. ; 19:6, s. 1655-1668
  • Tidskriftsartikel (refereegranskat)abstract
    • The Cluster spacecraft experienced several boundary layer encounters when flying outbound from the magnetosphere to the magnetosheath in the dusk sector on 14 January 2001. The dayside boundary layer was populated by magnetosheath electrons, but not with
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 10

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy